skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Springer Nature - Complete Springer Journals remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
JAK inhibition in the treatment of diabetic kidney disease
JAK inhibition in the treatment of diabetic kidney disease
Material Type:
Artigo 		Adicionar ao Meu Espaço

JAK inhibition in the treatment of diabetic kidney disease

Brosius, Frank C. ; Tuttle, Katherine R. ; Kretzler, Matthias

Diabetologia, 2016-08, Vol.59 (8), p.1624-1627 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
2
Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3
Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3
Material Type:
Artigo 		Adicionar ao Meu Espaço

Integration of fingerprint-based similarity searching and kernel-based partial least squares analysis to predict inhibitory activity against CSK, HER2, JAK1, JAK2, and JAK3

Deokar, Hemantkumar ; Deokar, Mrunalini ; Buolamwini, John K.

Molecular diversity, 2024-04, Vol.28 (2), p.497-507 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por
3
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies

Hurwitz, Herbert ; Van Cutsem, Eric ; Bendell, Johanna ; Hidalgo, Manuel ; Li, Chung-Pin ; Salvo, Marcelo Garrido ; Macarulla, Teresa ; Sahai, Vaibhav ; Sama, Ashwin ; Greeno, Edward ; Yu, Kenneth H. ; Verslype, Chris ; Dawkins, Fitzroy ; Walker, Chris ; Clark, Jason ; O’Reilly, Eileen M.

Investigational new drugs, 2018-08, Vol.36 (4), p.683-695 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por
4
Upadacitinib: First Approval
Upadacitinib: First Approval
Material Type:
Artigo 		Adicionar ao Meu Espaço

Upadacitinib: First Approval

Duggan, Sean ; Keam, Susan J.

Drugs (New York, N.Y.), 2019-11, Vol.79 (16), p.1819-1828 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por
5
Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop
Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop
Material Type:
Artigo 		Adicionar ao Meu Espaço

Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop

Bie, Caiqun ; Chen, Yanfang ; Tang, Huijun ; Li, Qing ; Zhong, Lu ; Peng, Xiaojuan ; Shi, Ying ; Lin, Junqin ; Lai, Junlong ; Wu, Shenglan ; Tang, Shaohui

Digestive diseases and sciences, 2022-02, Vol.67 (2), p.569-584 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por
6
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells
Material Type:
Artigo 		Adicionar ao Meu Espaço

Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells

Wang, Shaojun ; Zhang, Xiaofei ; Wang, Guimei ; Cao, Bin ; Yang, Hong ; Jin, Lipeng ; Cui, Mingjuan ; Mao, Yongjun

BMC cancer, 2019-11, Vol.19 (1), p.1160-1160, Article 1160 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
7
Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2
Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2

Song, Zhenghui ; Liu, Xinhui ; Zhang, Wan ; Luo, Yue ; Xiao, Hua ; Liu, Yun ; Dai, Guanqi ; Hong, Jian ; Li, Aimin

Journal of translational medicine, 2022-04, Vol.20 (1), p.157-157, Article 157 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
8
The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis
The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis
Material Type:
Artigo 		Adicionar ao Meu Espaço

The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis

Zhao, Jie ; O'Connor, Tracy ; Vassar, Robert

Journal of neuroinflammation, 2011-11, Vol.8 (1), p.150-150, Article 150 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
9
Ellagic Acid Ameliorates Renal Ischemic-Reperfusion Injury Through NOX4/JAK/STAT Signaling Pathway
Ellagic Acid Ameliorates Renal Ischemic-Reperfusion Injury Through NOX4/JAK/STAT Signaling Pathway
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ellagic Acid Ameliorates Renal Ischemic-Reperfusion Injury Through NOX4/JAK/STAT Signaling Pathway

Liu, Qiong ; Liang, Xiaobing ; Liang, Mintong ; Qin, Rongbin ; Qin, Feixing ; Wang, Xuelan

Inflammation, 2020-02, Vol.43 (1), p.298-309 [Periódico revisado por pares]

New York: Springer US

Texto completo disponível

Citações Citado por
10
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Namour, Florence ; Diderichsen, Paul Matthias ; Cox, Eugène ; Vayssière, Béatrice ; Van der Aa, Annegret ; Tasset, Chantal ; Van‘t Klooster, Gerben

Clinical pharmacokinetics, 2015-08, Vol.54 (8), p.859-874 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (203)
  2. Revistas revisadas por pares (204)

Data de Publicação 

De até
Refinar
  1. Antes de2001  (10)
  2. 2001Até2005  (17)
  3. 2006Até2010  (19)
  4. 2011Até2016  (55)
  5. Após 2016  (105)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.